Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks.
No Thumbnail Available
Identifiers
Date
2018-10-10
Authors
Olalla, Julián
Pérez-Stachowski, Javier
Tortajada, Begoña
Del Arco, Alfonso
Márquez, Efrén
De la Torre, Javier
Nieto, Miriam
García de Lomas, José María
Prada, José Luis
García-Alegría, Javier
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Generic drugs may help to support antiretroviral treatment. We want to assess the efficacy and safety at 24 weeks of the change of coformulated (abacavir + lamivudine + dolutegravir) to (abacavir + lamivudine) coformulated as a generic pharmaceutical specialty + dolutegravir. Between February and June 2017, switch from Triumeq® to a generic pharmaceutical specialty co-formulated tablet (abacavir + lamivudine) plus Tivicay® was made. Demographic, viroimmunological characteristics and the Charlson index were collected. Six months after switching, efficacy and safety were evaluated. Switch was made in 93 patients, with a mean age of 47 years, after six months there were five patients (5.4%) with viral loads between 50 and 400 copies, no patient had viral loads of greater amount. There were 2 interruptions due to toxicity (2.15%), in relation to symptoms of the central nervous system. There were no differences in the amount of years with HAART, nor in the previous months with the STR regimen based on abacavir + lamivudine + dolutegravir, nor in the Charlson index. The effective saving in 2017 derived from the change in these 93 patients was € 125.512. The change from a regimen of abacavir + lamivudine + dolutegravir seems to be safe and effective at 24 weeks.
Description
MeSH Terms
Anti-HIV Agents
Antiretroviral Therapy, Highly Active
Dideoxynucleosides
Drug Combinations
Drug Substitution
Drugs, Generic
Female
HIV Infections
Heterocyclic Compounds, 3-Ring
Humans
Lamivudine
Male
Middle Aged
Oxazines
Piperazines
Pyridones
Treatment Outcome
Viral Load
Antiretroviral Therapy, Highly Active
Dideoxynucleosides
Drug Combinations
Drug Substitution
Drugs, Generic
Female
HIV Infections
Heterocyclic Compounds, 3-Ring
Humans
Lamivudine
Male
Middle Aged
Oxazines
Piperazines
Pyridones
Treatment Outcome
Viral Load
DeCS Terms
CIE Terms
Keywords
Dolutegravir drugs, Generic drugs, HAART, Substitution HIV